Related Experiment Video

Updated: Sep 6, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials

Xiaogen Chen1, Chunna Jin1, Lan Xie1

  • 1Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Key Lab of Cardiovascular Disease of Zhejiang Province, Hangzhou, Zhejiang 310009, P. R. China.

Reviews in Cardiovascular Medicine
|April 8, 2020
PubMed

Insights

New heart failure (HF) drug LCZ696 shows superior renal protection compared to standard ACEI/ARB treatments. This finding offers hope for improved kidney function in HF patients receiving LCZ696 therapy.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Heart failure (HF) frequently co-occurs with renal insufficiency.
  • Standard treatments like ACE inhibitors/angiotensin receptor blockers (ACEI/ARB) may not fully protect kidney function in HF patients.
  • The renal protective effects of LCZ696 in HF patients compared to ACEI/ARB are not well-established.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the renal protective efficacy of LCZ696 versus ACEI/ARB in heart failure patients.
  • To compare the incidence of renal adverse events between LCZ696 and ACEI/ARB treatment groups.
  • To determine if LCZ696 offers superior kidney protection in the context of heart failure management.

Main Methods:

  • Systematic literature search of Embase, PubMed, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs).
  • Inclusion criteria focused on HF patients treated with either LCZ696 or ACEI/ARB, assessing renal adverse events.
  • Meta-analysis of data from 6 RCTs involving 14,959 patients, with the last search conducted on September 20, 2019.

Main Results:

  • LCZ696 significantly reduced the risk of renal function deterioration compared to ACEI/ARB.
  • The odds ratio for renal function deterioration with LCZ696 was 0.77 (95% CI 0.61-0.97, P = 0.02).
  • This meta-analysis suggests a statistically significant benefit of LCZ696 in preserving renal function.

Conclusions:

  • LCZ696 demonstrates potentially superior renal protection in heart failure patients when compared to ACEI/ARB.
  • The findings support the use of LCZ696 as a therapeutic option for mitigating renal decline in HF.
  • Further research may confirm LCZ696's role in comprehensive HF management, emphasizing renal health.

Keywords:
ACEI/ARBLCZ696heart failureworsening renal function

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...